A61K 47/6861
The tumour determinant being from kidney or bladder cancer cell
Official title: {the tumour determinant being from kidney or bladder cancer cell}
A61K47/6861 (The tumour determinant being from kidney or bladder cancer cell) appears on 149 US grants and 205 published applications in this corpus.
Search patents in A61K- Granted patents
- 149
- Published applications
- 205
- Assignees
- 62
- Inventors
- 256
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 3 |
| 2009 | 1 | 2 |
| 2010 | 0 | 4 |
| 2011 | 4 | 6 |
| 2012 | 1 | 5 |
| 2013 | 7 | 6 |
| 2014 | 5 | 24 |
| 2015 | 22 | 16 |
| 2016 | 25 | 29 |
| 2017 | 17 | 22 |
| 2018 | 14 | 13 |
| 2019 | 6 | 12 |
| 2020 | 10 | 12 |
| 2021 | 9 | 14 |
| 2022 | 8 | 8 |
| 2023 | 6 | 5 |
| 2024 | 3 | 10 |
| 2025 | 3 | 6 |
| 2026 | 3 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Use of anti-HER2 antibody-drug conjugate in treating urothelial carcinoma7 Jul 2026US 12,673,110 B2Remegen Co., Ltd.
- Functionalized enzyme-powered nanomotors26 May 2026US 12,636,352 B2Fundació Institut De Bioenginyeria De Catalunya
- Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives12 May 2026US 12,622,944 B2Ambrx, Inc.
- Hydrophilic antibody-drug conjugates25 Mar 2025US 12,257,281 B2Seagen Inc.
- Polynucleotides encoding antibodies which bind the EC3 domain of cadherin-6 (CDH6) and possess internalization ability25 Feb 2025US 12,233,155 B2Daiichi Sankyo Company, Limited
- Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives17 Sep 2026US 2026/0273017 A1Ambrx, Inc.
- Antibody drug conjugates (adc) that bind to 191p4d12 proteins5 Feb 2026US 2026/0034234 A1Agensys, Inc.
- Triple-payload antibody-drug conjugates (adcs)15 Jan 2026US 2026/0014265 A1Araris Biotech AG
- Humanized antibodies against nectin-4 and drug conjugates thereof15 Jan 2026US 2026/0014269 A1Nectin Therapeutics Ltd.
- Methods for Manipulating Phagocytosis Mediated by CD4730 Oct 2025US 2025/0333502 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Immunoconjugates with an intracellularly-cleavable linkage115US 7,999,083 B2Immunomedics, Inc. · 2011
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009
- Monoclonal antibodies to prostate cells103US 5,489,525 AThe United States of America as represented by the Department of Health and Human Services · 1996
- Immunoconjugates with an intracellularly-cleavable linkage85US 8,080,250 B1Immunomedics, Inc. · 2011
- Auristatin drug linker conjugates82US 8,609,105 B2Seattle Genetics, Inc. · 2013